Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 16Uterine Cervical Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Colonic Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Prostatic Neoplasms 2Neoplasms 2Hemangiosarcoma 2Diabetes Mellitus, Insulin-Dependent, 12 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Resectable MMR-deficient Solid Tumors 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Microsatellite Stable Rectal Carcinoma 1Melanoma 1Lymphoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Nivolumab 3Ipilimumab 3poly ICLC 2Specimen Handling 2Sorafenib 2Irinotecan 2Cyclophosphamide 2spartalizumab 1sapanisertib 1pembrolizumab 1fludarabine 1durvalumab 1dostarlimab 1dehydroftorafur 1balstilimab 1atezolizumab 1aflibercept 1Whole-Body Irradiation 1Watchful Waiting 1Vincristine 1Tacrolimus 1Sunitinib 1Prednisone 1Platinum 1Oxaliplatin 1Observation 1Mycophenolic Acid 1Mesna 1Leuprolide 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrolamellar hepatocellular carcinoma × balstilimab × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡